regulatory-science
(2)
Unlearn.AI
Unlearn.AI is a San Francisco biotech-AI company that builds disease-specific machine learning models to generate digital twins of clinical trial participants - longitudinal predictions of how each patient would have fared on placebo. Folded into a statistical method called PROCOVA and a trial design called TwinRCT, the approach lets sponsors shrink control arms by up to a third, so more patients receive the experimental drug while trials reach answers faster. Founded in 2017 by physicists Charles Fisher, Aaron Smith and Jon Walsh, the company has raised about $130M and earned a first-of-its-kind EMA qualification for an AI-based method to reduce sample size in pivotal trials.
Dan Riskin
Dan Riskin is a physician-entrepreneur, trauma surgeon, and healthcare AI executive who founded Verantos in 2015 to generate high-validity real-world evidence from messy clinical data. A serial innovator who began coding at age 5 and sold software at 12, Riskin holds an MD from Boston University and an MBA from MIT, is board-certified in four specialties, and serves as Clinical Professor of Surgery at Stanford. His prior company Health Fidelity was acquired for more than $150 million. Today, Verantos powers regulatory and reimbursement decisions for major pharmaceutical companies by turning fragmented EHR data into research-grade evidence at scale.